ID   KCL22-r
AC   CVCL_DP58
SY   KCL22-R; KCL22R
DR   ATCC; CRL-3350
DR   cancercelllines; CVCL_DP58
DR   PRIDE; PXD000030
DR   Wikidata; Q54899693
RX   PubMed=10910924;
RX   PubMed=17549412;
RX   PubMed=20417730;
RX   PubMed=23754495;
CC   Population: Japanese.
CC   Doubling time: 24-30 hours (ATCC=CRL-3350).
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (from parent cell line).
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 12
ST   D5S818: 10,11
ST   D7S820: 12
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2091 ! KCL-22
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=10910924; DOI=10.1182/blood.V96.3.1070;
RA   Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J.,
RA   Goldman J.M., Vaz de Melo J.;
RT   "Selection and characterization of BCR-ABL positive cell lines with
RT   differential sensitivity to the tyrosine kinase inhibitor STI571:
RT   diverse mechanisms of resistance.";
RL   Blood 96:1070-1079(2000).
//
RX   PubMed=17549412; DOI=10.3892/ijo.31.1.121;
RA   Hentschel J., Weise A., Michel S., Hennig K., Hartmann I.,
RA   Schiefner J., Schubert K., Liehr T., von Eggeling F.,
RA   Loncarevic I.F.;
RT   "Cytogenetic characterisation and proteomic profiling of the
RT   Imatinib-resistant cell line KCL22-R.";
RL   Int. J. Oncol. 31:121-128(2007).
//
RX   PubMed=20417730; DOI=10.1016/j.bbapap.2010.04.009;
RA   Colavita I., Esposito N., Martinelli R., Catanzano F., Vaz de Melo J.,
RA   Pane F., Ruoppolo M., Salvatore F.;
RT   "Gaining insights into the Bcr-Abl activity-independent mechanisms of
RT   resistance to imatinib mesylate in KCL22 cells: a comparative
RT   proteomic approach.";
RL   Biochim. Biophys. Acta 1804:1974-1987(2010).
//
RX   PubMed=23754495; DOI=10.1002/pmic.201200444;
RA   Colavita I., Esposito N., Quintarelli C., Nigro E., Pane F.,
RA   Ruoppolo M., Salvatore F.;
RT   "Identification of annexin A1 interacting proteins in chronic myeloid
RT   leukemia KCL22 cells.";
RL   Proteomics 13:2414-2418(2013).
//